Sept 22 (Reuters) - Activist investor Bluebell Capital
Partners has taken a small stake in British pharmaceuticals
group GlaxoSmithKline in efforts to shake up top
management, a Financial Times report https://www.ft.com/content/539c077d-6ac2-4e79-9e0f-8080a31c5530
said on Wednesday.
In a letter sent to GSK's chairman Jonathan Symonds,
Bluebell called for chief executive Emma Walmsley to reapply for
her job as she would have “renewed credibility both internally
and externally”, the FT report said.
Earlier this year, activist Elliott had also taken a stake
in GSK, calling for a leadership change at the company.
(Reporting by Aditi Sebastian in Bengaluru. Editing by Jane
Merriman)
Glaxosmithkline (GSK)
